Background: Although rare, Guillain-Barré Syndrome (GBS) has a high economic burden, with consequences for families and society. This study aimed to estimate the total cost of GBS, per individual and per variant of the disease, as well as its effect on household income, from the perspective of patients.
Methods: This was a cost-of-illness study from the perspective of patients and their families, with a time horizon from disease onset to 6 mo after discharge. The total cost of GBS was estimated by bottom-up microcosting, considering direct and indirect costs.
Results: The median cost of GBS per individual was US$1635.5, with direct costs accounting for 64.3% of this amount. Among the variants analyzed, acute motor sensory axonal neuropathy (US$4660.1) and acute inflammatory demyelinating polyneuropathy (US$2017.0) exhibited the highest costs compared with acute motor axonal neuropathy (US$1635.5) and Miller Fisher Syndrome (US$1464.8). The costs involved compromise more than 20% of the household income of 22 (47.8%) patients.
Conclusions: This study demonstrated how costly GBS can be. It is hoped that decision-makers will analyze these results with a view to improving the structure of healthcare services.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/trstmh/trab118 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atomistic Probing and Identification of Point Defects and Grain Boundaries of 1H and 1T' Molybdenum Telluride Monolayer.
Inorg Chem
January 2025
School of Materials Science and Engineering, Taizhou University, Taizhou 318000, China.
The substantial structural defects frequently observed in fabricated transition-metal dichalcogenide (TMD) samples inevitably affect the device performance. The molybdenum telluride (MoTe) monolayer can easily generate phase transitions between the 1H and 1T' phases due to a small energy barrier. However, distinguishing and identifying various defects during experiments is challenging.
View Article and Find Full Text PDFManagement of severe pediatric Guillain-Barré syndrome in a low-income country: efficacy and safety of therapeutic plasma exchange in pediatric patients: a retrospective study.
BMC Pediatr
December 2024
Faculty of Medicine, Al-Baath University, Al-Sham Street, Homs, Syria.
Background: Guillain-Barré syndrome (GBS) is an autoimmune disease that affects the peripheral nervous system leading to motor, sensory, and sometimes autonomic manifestations. Therapeutic plasma exchange (TPE), which involves the selective removal of pathological molecules, such as auto-antibodies, from plasma, has proven to be safe and effective in adults with GBS. However, its application in pediatric patients lacks sufficient evidence.
View Article and Find Full Text PDFPoint defects at grain boundaries can create structural instabilities and persistent deep traps in metal halide perovskites.
Nanoscale
December 2024
Department of Chemistry, University of Southern California, Los Angeles, CA 90089, USA.
Article Synopsis
- Metal halide perovskites (MHPs) are popular for their low cost and performance, aided by their unique defect dynamics.
- Research focused on how defects like grain boundaries and lead interstitials create new chemical species that destabilize material properties, preventing recovery to their original structure.
- Long-lasting defects at grain boundaries negatively affect charge mobility and lifetime, emphasizing the need for effective strategies to manage these defects for improved performance.
Microresonator frequency comb-based high-speed data transmission provides a pathway towards augmented data capacity without increasing the number of laser sources. Their use with intensity-modulated direct detection modulation (IMDD) formats is especially pertinent in data center communications where minimizing cost, latency and complexity is paramount. This however implies that the same extent of digital signal processing techniques commonly used in coherent detection for the management of fiber impairments including chromatic dispersion are not available.
View Article and Find Full Text PDFPersistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis.
Eur J Neurol
January 2025
Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau; and Institut de Recerca Sant Pau, IR-SantPau, Barcelona, Spain.
Article Synopsis
- The study focuses on long-term outcomes and healthcare resource utilization in patients with generalized myasthenia gravis (gMG).
- About 220 patients were analyzed over eight years, showing significant improvement in daily living scores and a reduction in healthcare costs, although some patients continued to experience symptoms and drug-related adverse events.
- The findings suggest that while most patients experience positive outcomes, a minority still suffer from persistent symptoms and side effects, highlighting the ongoing burden of gMG on both patients and healthcare systems.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!